Hayato Hikita, Tetsuo Takehara, Satoshi Shimizu, Takahiro Kodama, Minoru Shigekawa, Kyoko Iwase, Atsushi Hosui, Takuya Miyagi, Tomohide Tatsumi, Hisashi Ishida, Wei Li, Tatsuya Kanto, Naoki Hiramatsu, Norio Hayashi – 16 July 2010 – Tumor cells are characterized by uncontrolled proliferation, often driven by activation of oncogenes, and apoptosis resistance.
Gian Luigi Adani, Anna Rossetto, Vittorio Bresadola, Umberto Baccarani – 16 July 2010
Sumeet K. Asrani, Michael D. Leise, Colin P. West, M. Hassan Murad, Rachel A. Pedersen, Patricia J. Erwin, Jianmin Tian, Russell H. Wiesner, W. Ray Kim – 16 July 2010 – Sirolimus is used in patients with renal insufficiency after liver transplantation (LT) and especially in those with calcineurin inhibitor (CNI)–associated nephrotoxicity.
Sung Hwan Ki, Oygi Park, Mingquan Zheng, Oriol Morales‐Ibanez, Jay K. Kolls, Ramon Bataller, Bin Gao – 16 July 2010 – Interleukin‐22 (IL‐22), a recently identified member of the IL‐10 family of cytokines that is produced by Th17 and natural killer cells, plays an important role in controlling bacterial infection, homeostasis, and tissue repair. Here, we tested the effect of IL‐22 on alcohol‐induced liver injury in a murine model of chronic‐binge ethanol feeding.
James Neuberger, Sue Madden, David Collett – 16 July 2010 – The assessment of outcomes after transplantation is important for several reasons: it provides patients with data so that they can make informed decisions about the benefits of transplantation and the success of the transplant unit; it informs commissioners that resources are allocated properly; and it provides clinicians reassurance that results are acceptable or, if they are not, provides early warning so that problems can be identified, corrections can be instituted early, and all interested parties can be reassured that scarce
Eliane Tiemi Miyazaki, Randolfo dos Santos, M. Cristina Miyazaki, Neide M. Domingos, Hellen C. Felicio, Marcia F. Rocha, Paulo C. Arroyo, William J. Duca, Renato F. Silva, Rita C. M. A. Silva – 16 July 2010 – Over the last few decades, informal caregivers of patients with chronic diseases have received more attention, and there is a growing volume of studies demonstrating high rates of burden, stress, and mental disorders in this group of individuals.
Yunfang Wang, Hsin‐Lei Yao, Cai‐Bin Cui, Eliane Wauthier, Claire Barbier, Martin J. Costello, Nicholas Moss, Mitsuo Yamauchi, Marnisa Sricholpech, David Gerber, Elizabeth G. Loboa, Lola M. Reid – 30 June 2010 – The differentiation of embryonic or determined stem cell populations into adult liver fates under known conditions yields cells with some adult‐specific genes but not others, aberrant regulation of one or more genes, and variations in the results from experiment to experiment.
Edith M. M. Kuiper, Karel J. van Erpecum, Ulrich Beuers, Bettina E. Hansen, H. Bing Thio, Robert A. de Man, Harry L. A. Janssen, Henk R. van Buuren – 30 June 2010 – Colesevelam is an anion‐exchange resin with a 7‐fold higher bile acid–binding capacity and fewer side effects than cholestyramine, the current first‐line treatment option for cholestatic pruritus. The aim of this trial was to compare the effects of colesevelam and a placebo in patients with cholestatic pruritus.
Hui Xu, Jie‐Hua He, Zhen‐Dong Xiao, Qian‐Qian Zhang, Yue‐Qin Chen, Hui Zhou, Liang‐Hu Qu – 30 June 2010 – MicroRNA‐122 (miR‐122) is a liver‐specific microRNA whose expression is specifically turned on in the mouse liver during embryogenesis, thus it is expected to be involved in liver development. However, the role of miR‐122 in liver development and its potential underlying mechanism remain unclear.
Philippe Ichai, Faouzi Saliba, Fadi Antoun, Daniel Azoulay, Mylène Sebagh, Teresa Maria Antonini, Lélia Escaut, Delvart Valérie, Denis Castaing, Didier Samuel – 30 June 2010 – The standard antitubercular treatment (ATT), which consists of isoniazid (INH), rifampicin (RIF), ethambutol, and pyrazinamide (PZA), is the best available treatment for tuberculosis (TB). However, the hepatotoxicity of INH and PZA can be severe, and even after drug withdrawal, patients may require liver transplantation (LT). In these cases, the strategy for the treatment of TB is poorly defined.